BKM120 in Cancers With PIK3CA Activating Mutations

This study has been withdrawn prior to enrollment.
(The study has been closed due to lack of accrual)
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Jeffrey Engelman, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01501604
First received: December 27, 2011
Last updated: September 16, 2015
Last verified: September 2015
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Study Completion Date: August 2013
  Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)